KRYSTAL BIOTECH INC. - COMMON STOCK

Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa

29 11 2021 06:00:00 提供 Nasdaq GlobeNewswire

Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress

08 11 2021 06:00:01 提供 Nasdaq GlobeNewswire

Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

26 10 2021 06:00:00 提供 Nasdaq GlobeNewswire

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis

19 10 2021 15:05:00 提供 Nasdaq GlobeNewswire

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT

14 10 2021 06:00:00 提供 Nasdaq GlobeNewswire

Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)

12 10 2021 07:00:02 提供 Nasdaq GlobeNewswire

Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference

01 10 2021 15:01:00 提供 Nasdaq GlobeNewswire

Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis

29 9 2021 07:00:01 提供 Nasdaq GlobeNewswire

Krystal Biotech Appoints Laurent Goux as General Manager of Europe

15 9 2021 07:00:01 提供 Nasdaq GlobeNewswire

Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021

09 9 2021 07:00:02 提供 Nasdaq GlobeNewswire

Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

07 9 2021 15:31:00 提供 Nasdaq GlobeNewswire

Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress

09 8 2021 07:00:01 提供 Nasdaq GlobeNewswire

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

01 7 2021 15:15:00 提供 Nasdaq GlobeNewswire

Krystal Biotech to Participate in Upcoming Investor Conferences

03 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress

10 5 2021 07:00:01 提供 Nasdaq GlobeNewswire

Krystal Biotech Appoints Andy Orth as Chief Commercial Officer

03 5 2021 07:00:01 提供 Nasdaq GlobeNewswire

Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT

27 4 2021 15:35:00 提供 Nasdaq GlobeNewswire

Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB

26 4 2021 15:05:00 提供 Nasdaq GlobeNewswire

Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline

19 4 2021 07:00:01 提供 Nasdaq GlobeNewswire

Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

30 3 2021 07:00:02 提供 Nasdaq GlobeNewswire